SUNITINIB SUN sunitinib (as malate) 25 mg capsule bottle

Země: Austrálie

Jazyk: angličtina

Zdroj: Department of Health (Therapeutic Goods Administration)

Aktivní složka:

sunitinib malate, Quantity: 33.413 mg (Equivalent: sunitinib, Qty 25 mg)

Dostupné s:

Sun Pharma ANZ Pty Ltd

Léková forma:

Capsule, hard

Složení:

Excipient Ingredients: Gelatin; mannitol; magnesium stearate; iron oxide red; titanium dioxide; purified water; croscarmellose sodium; povidone; iron oxide yellow; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; Shellac; ethanol absolute; ammonia; potassium hydroxide

Podání:

Oral

Jednotky v balení:

28 capsules

Druh předpisu:

(S4) Prescription Only Medicine

Terapeutické indikace:

SUNITINIB SUN is indicated for:,? treatment of advanced renal cell carcinoma (RCC),? treatment of gastrointestinal stromal tumour (GIST) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic NET).

Přehled produktů:

Visual Identification: Hard gelatin Size 3 capsule with opaque caramel cap and opaque reddish brown body, self-lock capsule, imprinted with RM54 on the cap and RM54 on body in white ink; Container Type: Bottle; Container Material: HDPE; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Stav Autorizace:

Registered

Datum autorizace:

2021-02-22